Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 May;29(5):629-637.
doi: 10.1007/s10147-024-02489-0. Epub 2024 Apr 2.

Magnesium supplementation therapy to prevent cisplatin-induced acute nephrotoxicity in pediatric cancer: a randomized phase-2 trial

Motohiro Matsui  1   2 , Atsushi Makimoto  3 , Motoaki Chin  4 , Katsuyoshi Koh  5 , Masako Tomotsune  6 , Tetsuji Kaneko  6 , Yoshihiko Morikawa  6 , Riku Hamada  7 , Yuki Yuza  3
Affiliations
Clinical Trial

Magnesium supplementation therapy to prevent cisplatin-induced acute nephrotoxicity in pediatric cancer: a randomized phase-2 trial

Motohiro Matsui et al. Int J Clin Oncol. 2024 May.

Abstract

Background: The present study aimed to examine the effect of magnesium (Mg) supplementation on cisplatin-induced nephrotoxicity (CIN) in pediatric cancer patients.

Methods: The present phase-2, open-label, multicenter, randomized controlled trial enrolled patients aged less than 20 years who were scheduled to receive cisplatin-containing chemotherapy and randomly allocated them at a ratio of 1:1 to a Mg supplementation arm with even-numbered chemotherapy courses (arm AB) or another arm with odd-numbered courses (arm BA). Analysis objects were reconstructed into two groups depending on whether the chemotherapy course had Mg supplementation (group B) or not (group A). The primary outcome was the proportion of chemotherapy courses resulting in elevated serum creatinine per chemotherapy course. The secondary outcomes included efficacies evaluated using other biomarkers and the safety of the Mg supplementation.

Results: Twenty-eight patients were randomly allocated to either group (16 to arm AB and 12 to arm BA). The baseline characteristics of the groups were similar. There was no significant difference in the proportion of courses with increased serum creatinine between the groups (group A: 10% vs. group B: 6%; P = 0.465) nor was any significant difference observed in other biomarkers during any chemotherapy course. The Mg value during chemotherapy was significantly higher in group B than that in group A. No adverse events related to magnesium administration were observed.

Conclusions: The study design, which treated a single chemotherapy course as a study object, failed to detect a statistically significant benefit of Mg supplementation for preventing CIN in pediatric cancer patients.

Trial registration: JRCT ( https://jrct.niph.go.jp/ ) Identifier UMIN000029215 jRCTs031180251. UMIN-CTR ( http://www.umin.ac.jp/icdr/index.html ) Identifier UMIN000029215.

Keywords: Cisplatin; Magnesium; Nephrotoxicity; Pediatric cancer.

PubMed Disclaimer

References

    1. W. Landier, S.H. Armenian, A.T. Meadows, et al. Late effects of childhood cancer and its treatment. P.A. Pizzo, D.G. Poplack (Eds.), Principles and Practice of Pediatric Oncology (seventh ed.), Wolters Kluwer, Philadelphia (2016). 1173–1196
    1. Chirino YI, Pedraza-Chaverri J (2009) Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol 61:223–242 - DOI - PubMed
    1. Sanchez-Gonzalez PD, Lopez-Hernandez FJ, Lopez-Novoa JM et al (2011) An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity. Crit Rev Toxicol 41:803–821 - DOI - PubMed
    1. Cvitkovic E, Spaulding J, Bethune V et al (1977) Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer 39:1357–1361 - DOI - PubMed
    1. Hayes DM, Cvitkovic E, Golbey RB et al (1977) High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 39:1372–1381 - DOI - PubMed

Publication types

LinkOut - more resources